advertisement
Abstract #19312 Published in IGR 9-3
Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension
Mundorf T; Noecker RJ; Earl MAdvances in Therapy 2007; 24: 302-309
This study was undertaken to evaluate the ocular hypotensive efficacy of brimonidine Purite ® 0.15%. (Alphagan(registered trademark) P 0.15%; Allergan, Inc., Irvine, Calif) given as adjunctive therapy with latanoprost 0.005% (Xalatan®, Pfizer Inc., New York, NY) to patients with open-angle glaucoma or ocular hypertension. In this multicenter, open-label, prospective evaluation, the intraocular pressure (IOP) of the 43 enrolled patients was ≥ 18 mmHg after at least 6 wk of latanoprost monotherapy. The primary outcome measure was IOP at peak drug effect (10 AM, or approximately 2 h after the morning close of brimonidine 0.15%). IOP at trough drug effect (8 AM, or approximately 12 h after the evening dose of brimonidine) was also measured. Baseline IOP was 21.9 (± 2.3) mmHg. After 1 mo of treatment, additional mean IOP reductions from latanoprost-treated baseline values were 5.8 mmHg (26%) at peak drug effect (P < .001) and 3.3 mmHg (15%) at trough (P < .001). At the month 2 visit, additional mean IOP reductions from latanoprost-treated baseline values were 5.1 mmHg (23%) at peak drug effect (P < .001) and 2.0 mmHg (9%) at trough (P = .002). Brimonidine Purite 0.15% provided statistically significant additional reductions in IOP from latanoprost-treated baseline values. These findings suggest that brimonidine Purite 0.15% is an efficacious adjunctive therapy in patients given latanoprost who require additional lowering of IOP.
Dr. R.J. Noecker, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, 203 Lothrop Street, Pittsburgh, PA 15213, USA. noeckerrj@upmc.edu
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
